Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody variable domains targeting the nkg2d receptor

A structural domain and variable technology, applied in the direction of antibody, receptor/cell surface antigen/cell surface determinant, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve problems such as adverse side effects

Pending Publication Date: 2021-02-12
DRAGONFLY THERAPEUTICS INC
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current treatment options for these cancers are not effective in all patients and / or may have serious adverse side effects
Treating other types of cancer with existing treatment options also remains challenging

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody variable domains targeting the nkg2d receptor
  • Antibody variable domains targeting the nkg2d receptor
  • Antibody variable domains targeting the nkg2d receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0181] Example 1 - Binding affinity of various NKG2D binding domains

[0182] The kinetics and affinities of various NKG2D binding domains were assessed by surface plasmon resonance using a Biacore 8K instrument (GE Healthcare). Anti-human Fc antibodies were immobilized on CM5 chips using standard amine coupling chemistry. Human monoclonal antibodies containing various NKG2D binding domains were captured on an anti-human Fc chip at a density of approximately 100 RU. A solution containing 0.411-100 nM soluble mouse Fc-human NKG2D dimer was injected at 30 μl / min at 37°C onto the captured NKG2D antibody and control surfaces. Surfaces were regenerated between cycles by rapid injection of 10 mM glycine pH 1.8. To obtain kinetic rate constants, bi-reference data were fitted to a 1:1 interaction model using Biacore 8K evaluation software (GE Healthcare). Equilibrium binding constant K D by the dissociation constant k d with the association constant k a ratio (k d / k a )Sure. ...

Embodiment 2

[0184] Example 2 - Binding epitope clustering of ADI-27744 clones

[0185] Clustering of ADI-27744(A44) NKG2D-binding domains was performed by surface plasmon resonance on a series of antibodies and ULBP6, the natural ligand for NKG2D, using a Biacore 8K instrument. Briefly, mouse Fc-human NKG2D was captured at a density of approximately 100 RU using an anti-mouse Fc antibody immobilized on a CM5 chip. Antibodies including ADI-27744, ADI-27749, F47 (sequence listed below) or 1D11 (commercial monoclonal NKG2D antibody), ULBP6 (sequence listed below), NKG2D monoclonal antibodies of MS (NKG2D antibody from Novo Nordisk, sequence listed below) and MAB139 (NKG2D antibody from R&D system, clone 149810). Biacore 8K evaluation software was used for all data analysis.

[0186] Table 10

[0187]

[0188]

[0189] ULBP amino acid sequence SEQ ID NO:67:

[0190]

[0191] Figure 4A A profile of NKG2D monoclonal antibody containing ADI-27744 injected on immobilized NKG2D foll...

Embodiment 3- 3

[0193] Example 3 - Trispecific Binding Protein Binding to NKG2D

[0194] The EL4 mouse lymphoma cell line was engineered to express human NKG2D. detect as figure 1 Shown is the effect of trispecific binding proteins (TriNKETs) each containing an NKG2D binding domain, a tumor-associated antigen binding domain (such as a CD33 or HER2 binding domain), and a CD16-binding Fc domain on extracellular NKG2D expressed on EL4 cells. affinity. Binding of multispecific binding proteins to NKG2D was detected using a fluorophore-conjugated anti-human IgG secondary antibody. Cells were analyzed by flow cytometry and fold-over-background (FOB) was calculated using mean fluorescence intensity (MFI) of NKG2D-expressing cells compared to parental EL4 cells.

[0195] TriNKETs tested included CD33-TriNKET-A44 (ADI-27744 and CD33 binding domain), CD33-TriNKET-A49 (ADI-27749 and CD33 binding domain), CD33-TriNKET-F63 (ADI-29463 and CD33 binding domain ), HER2-TriNKET-A44 (ADI-27744 and CD33 bind...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described.Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Patent Application No. 62 / 628,161, filed February 8, 2018, the disclosure of which is incorporated by reference in its entirety for all purposes; and U.S. Provisional Patent Application No. 62, filed August 8, 2018 / Benefits and Priorities of No. 716,259. [0003] field of invention [0004] The present invention provides proteins having antibody heavy and light chain variable domains that can pair to form natural killer group 2D (NKG2D) receptors that target natural killer cells Antigen binding sites of , pharmaceutical compositions comprising such proteins, and methods of treatment using such proteins and pharmaceutical compositions, including for the treatment of cancer. Background technique [0005] Despite numerous research efforts and scientific advances reported in the literature for the treatment of the disease, cancer remains an important health problem. Some of the mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K39/395C07K14/705C07K16/28
CPCA61P35/00C07K16/2851C07K2317/24C07K2317/31C07K2317/35C07K2317/622C07K2317/64C07K2317/73C07K2317/76C07K2317/94C07K16/2803C07K16/32C07K2317/52C07K2317/732A61K38/00C07K14/7056C07K2317/70C07K2317/565C07K2317/92C07K16/28C07K16/283A61K2039/505C07K2317/56
Inventor 格雷戈里·P·常安·F·张阿斯亚·格林贝格威廉·哈尼布拉德利·M·伦德比昂卡·普林茨
Owner DRAGONFLY THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com